Treatment of Frontotemporal Dementia
Cholinesterase inhibitors and memantine should NOT be used for frontotemporal dementia and should be discontinued if already prescribed, as they provide no benefit and may worsen symptoms. 1
Pharmacological Management
What NOT to Use
The 2020 Canadian Consensus Conference provides clear, high-quality guideline evidence that:
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) should be discontinued in FTD patients (Grade 1B recommendation, 93% consensus) 1
- Memantine should be discontinued in FTD patients (Grade 1C recommendation, 91% consensus) 1
These medications are only indicated for Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia, and vascular dementia—NOT for frontotemporal dementia or other neurodegenerative conditions. Unlike in Alzheimer's disease where these drugs may provide modest benefit, in FTD they offer no cognitive or functional improvement and can actually exacerbate neuropsychiatric symptoms 2, 3.
Symptomatic Treatment Options
Currently, no FDA-approved disease-modifying or symptomatic treatments exist for FTD 2, 4, 5. Management relies entirely on off-label medication use with limited evidence:
For behavioral symptoms:
- Selective serotonin reuptake inhibitors (SSRIs) show the most promise and are the first-line pharmacological option for managing behavioral disturbances, apathy, and compulsive behaviors 3, 5
- Antipsychotics and anti-epileptics have only case report evidence and carry significant risks (confusion, parkinsonism, increased mortality), so use cautiously and only when behavioral symptoms pose safety risks 4, 5
For motor symptoms (when FTD overlaps with parkinsonism):
- Most FTD-related parkinsonism does NOT respond to levodopa, unlike idiopathic Parkinson's disease 5
- A trial of carbidopa-levodopa may be attempted, but only a small percentage show improvement 5
- Riluzole is indicated only when FTD overlaps with amyotrophic lateral sclerosis (ALS) 5
Non-Pharmacological Management (Primary Treatment Approach)
Given the lack of effective pharmacological options, non-pharmacological interventions form the cornerstone of FTD management 6, 2:
- Speech therapy for language variants (primary progressive aphasia), apraxia, and dysarthria 5
- Occupational therapy to maintain functional abilities and adapt the environment 5
- Physical therapy for motor symptoms and maintaining mobility 5
- Caregiver education and support is critical, as discrepancies between patient self-awareness and actual deficits are profound 7
- Case management to coordinate care delivery and social support services (Grade 2B recommendation) 1
- Safety planning addressing driving, financial management, and wandering behaviors
Critical Clinical Pitfalls
Do not treat FTD like Alzheimer's disease—the pathophysiology is fundamentally different (tau/TDP-43 aggregates vs. amyloid plaques), and Alzheimer's medications worsen FTD symptoms 2, 3
Behavioral symptoms in FTD do not qualitatively differ between behavioral-variant FTD and semantic dementia—they differ only in severity 7. Both subtypes show apathy, impulsivity, and challenging behaviors across a spectrum.
Patient self-reporting is unreliable—there are strong discrepancies between patient and caregiver perspectives due to lack of insight 7. Always obtain collateral history from caregivers.
Apathy correlates with executive dysfunction and anterior cingulate atrophy, not with social-semantic knowledge deficits 7. This has implications for targeting interventions.
Future Directions
Multiple Phase I/II clinical trials are underway targeting:
- Progranulin gene mutations
- C9orf72 gene expansions
- Tau protein aggregation
- TDP-43 pathology
However, disease-modifying treatments remain years away, as evidenced by recent Phase III failures of tau aggregation inhibitors 8, 3. Current management must focus on symptomatic relief and quality of life optimization through non-pharmacological means.